Edition:
United States

Hutchison China MediTech Ltd (HCM.OQ)

HCM.OQ on NASDAQ Stock Exchange Global Select Market

31.11USD
22 Jun 2018
Change (% chg)

$0.70 (+2.30%)
Prev Close
$30.41
Open
$31.04
Day's High
$31.19
Day's Low
$30.31
Volume
19,783
Avg. Vol
28,339
52-wk High
$42.00
52-wk Low
$21.80

Latest Key Developments (Source: Significant Developments)

Hutchison China Meditech says ‍underwriters elected to purchase an additional 1.5 mln ADSs
Friday, 27 Oct 2017 07:10am EDT 

Oct 27 (Reuters) - Hutchison China Meditech Ltd :UNDERWRITERS HAVE ELECTED TO PURCHASE AN ADDITIONAL 1.5 MILLION ADSS AT OFFERING PRICE OF US$26.50 PER ADS.‍TOTAL GROSS PROCEEDS OF OFFERING IS APPROXIMATELY US$301.3 MILLION​.  Full Article

Chi-Med reports preliminary phase II data on fruquintinib combination
Monday, 16 Oct 2017 02:00am EDT 

Oct 16 (Reuters) - Hutchison China Meditech Ltd :CHI-MED REPORTS PRELIMINARY PHASE II DATA ON FRUQUINTINIB COMBINATION IN FIRST-LINE LUNG CANCER.HUTCHISON CHINA MEDITECH LTD SAYS ‍PRELIMINARY RESULTS IN 17 EFFICACY EVALUABLE PATIENTS SHOWED AN ORR OF 76 PERCENT AND A DCR OF 100 PERCENT​.HUTCHISON CHINA MEDITECH LTD SAYS ‍PRELIMINARY DATA FROM PHASE II TRIAL DEMONSTRATED PROMISING EFFICACY AND AN ACCEPTABLE SAFETY PROFILE​.  Full Article

Hutchison China Meditech Ltd says may offer to sell in one or more offerings ADS representing ordinary shares
Monday, 3 Apr 2017 07:59am EDT 

Hutchison China Meditech Ltd :Hutchison China Meditech Ltd - files to say may offer to sell in one or more offerings American Depositary Shares representing ordinary shares - SEC filing.  Full Article

Hutchison China Meditech FY group revenue up 21 pct
Monday, 13 Mar 2017 03:00am EDT 

Hutchison China Meditech Ltd : FY group revenue up 21 pct to $216.1 million .FY net income attributable to Chi-Med of $11.7 million versus $8.0 million year ago.  Full Article

Hutchison China Meditech H1 group revenue up 27 pct to $104.5 mln
Tuesday, 2 Aug 2016 02:00am EDT 

Hutchison China Meditech Ltd : Says h1 group revenue up 27% to $104.5 million (h1 2015: $82.5m . Says h1 consolidated revenue up 27% to $104.5 million (h1 2015: $82.5m) .Sees fy 2016 consolidated revenue $190-205 million.  Full Article

Hutchison China, AstraZeneca amend savolitinib co-development agreement
Monday, 1 Aug 2016 02:21am EDT 

Hutchison China Meditech : Co and astrazeneca amend co-development agreement to accelerate savolitinib global development program; .Amendment provides that chi-med will contribute up to $50 million, spread primarily over three years.  Full Article

No consensus analysis data available.